1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Humanigen, Inc.

Humanigen, Inc.

HGENQ
Humanigen, Inc.US flagOther OTC
0.00
USD
- -
- -
23,816.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
338.03
419
116.38
0.07
- -
- -
- -
- -
- -
- -
0.01
0.06
0.03
0.02
Basic EPS, GAAP
-97.33
-46.17
-448.66
-69.13
-46.09
-42.88
-13.92
-7.34
-0.63
-0.46
-2.42
-4.04
-0.79
-0.55
Free Cash Flow per Basic Share
273.54
-326.7
-456.62
-64.54
-44.13
-35.39
-10.8
-4.76
-0.33
-0.18
-1.89
-3.14
-0.86
-0.66
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1,384.1
-1,546.43
-1,875.36
-231.03
-216.15
-258.89
-123.92
-87.67
-14.48
-12.74
-10.13
-10.44
-7.64
-7.07
Tangible Book Value per Share
-1,347.86
-3,219.5
-3,759.91
99.77
29.85
6.95
-2.26
-8.13
-0.43
-0.64
1.23
-0.4
-0.52
-0.51
Basic Weighted Avg Shares
- -
- -
- -
1
1
1
2
3
19
22
37
59
89
97
Sales/Revenue/Turnover
18
20
6
- -
- -
- -
- -
- -
- -
- -
- -
4
3
2
Operating Margin (%)
-34.57
-11.19
-385.08
-92,975
- -
- -
- -
- -
- -
- -
-28,268.59
-6,474.88
-2,716.95
-3,061.21
Depreciation Expense
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-5
-2
-24
-42
-38
-35
-27
-22
-12
-10
-90
-237
-71
-54
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-28.79
-11.02
-385.52
-95,336.36
- -
- -
- -
- -
- -
- -
-28,697.12
-6,582.73
-2,813.44
-3,156.8
Working Capital
16
10
14
66
24
10
-3
-23
-7
-13
48
2
-45
-48
LT Debt
- -
- -
10
7
- -
- -
1
1
1
1
- -
25
- -
- -
Total Equity
-70
-72
-95
61
25
6
-4
-24
-8
-14
46
-24
-47
-50
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.73
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
119
119
119
Market Capitalization
14
10
14

Working Capital

FRC

•

in mil. unless spec.
Sep'22
Dec'22
Mar'23
Total Current Assets
26
11
5
Cash, Cash Equivalents & STI
25
10
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
76
56
53
Payables & Accruals
76
55
52
ST Debt
- -
- -
- -
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-48.33%
-92.56%
97.42%
Free Cash Flow
163.61%
331.89%
-58.33%
Net Income, GAAP
82.42%
160.87%
-70.11%
Sales/Revenue/Turnover
- -
- -
-30.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
1
1
1
4
2022
1
1
- -
- -
3
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-1.25
-1.2
-1.12
- -
-4.04
2022
-0.32
-0.43
-0.23
- -
-0.79
2023
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Cameron Durrant MBA
Full Time Employees
6
Sector
Healthcare
Industry
Biotechnology
Address
830 Morris Turnpike Short Hills NJ United States of America 07078-2625
IPO Date
Jan 31, 2013
Website
humanigen.com
Similar Companies
Kyverna Therapeutics, Inc. (KYTX)
Statera Biopharma, Inc. (STAB)
Cardax, Inc. (CDXI)
Feng Chi Biotech Corp. (6744.TWO)
Argenica Therapeutics Ltd (AGN.AX)
Ultragenyx Pharmaceutical Inc. (RARE)
Business
Humanigen, Inc. operated as a biopharmaceutical firm focused on the clinical development of treatments to modulate immune responses. The company's primary investigational compound was lenzilumab, a monoclonal antibody engineered to specifically bind and neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF). This therapeutic candidate was explored for its potential to mitigate cytokine storm, notably in patients hospitalized with COVID-19, for which it advanced through a Phase 3 study and an additional Phase 2/3 investigation supported by the National Institutes of Health. Beyond respiratory illnesses, lenzilumab was also studied in conjunction with CD19-targeted CAR-T cell therapies and for other inflammatory conditions such as acute Graft versus Host Disease in individuals undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. Furthermore, research extended to lenzilumab's application in patients diagnosed with chronic myelomonocytic leukemia presenting RAS pathway mutations. The company's developmental portfolio also featured other proprietary Humaneered monoclonal antibodies, including ifabotuzumab, which targets EphA3, and HGEN005, designed to bind EMR1. These agents were being developed for a spectrum of eosinophilic disorders, encompassing eosinophilic leukemia, both as a standalone antibody and as a foundation for innovative CAR-T constructs. Founded in 2000 and headquartered in Short Hills, New Jersey, Humanigen encountered significant challenges, including the denial of Emergency Use Authorization for lenzilumab in COVID-19 by the U.S. Food and Drug Administration in September 2021. These difficulties ultimately led to the company filing a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware on January 3, 2024. Subsequently, in February 2024, substantially all of Humanigen's assets, including its key drug candidates lenzilumab and ifabotuzumab along with their associated clinical data and intellectual property, were acquired by Taran Therapeutics Inc., an entity formed by the former CEO. Humanigen's stock was delisted from Nasdaq in October 2023 and currently trades under HGENQ on the OTC Pink sheets.